X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5057) 5057
atorvastatin calcium (4490) 4490
male (3936) 3936
atorvastatin (3635) 3635
female (3120) 3120
middle aged (2685) 2685
statins (2518) 2518
pyrroles - therapeutic use (2249) 2249
heptanoic acids - therapeutic use (2247) 2247
aged (2000) 2000
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (1997) 1997
animals (1601) 1601
cholesterol (1491) 1491
pharmacology & pharmacy (1467) 1467
pyrroles - pharmacology (1430) 1430
heptanoic acids - pharmacology (1428) 1428
adult (1358) 1358
cardiac & cardiovascular systems (1347) 1347
treatment outcome (1318) 1318
simvastatin (1297) 1297
pyrroles - administration & dosage (1141) 1141
heptanoic acids - administration & dosage (1140) 1140
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (1120) 1120
anticholesteremic agents - therapeutic use (1009) 1009
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (984) 984
cholesterol, ldl - blood (957) 957
atherosclerosis (905) 905
risk factors (878) 878
pravastatin (772) 772
rats (763) 763
antilipemic agents (746) 746
dose-response relationship, drug (721) 721
lipids (719) 719
hypercholesterolemia - drug therapy (718) 718
risk (713) 713
rosuvastatin (659) 659
inflammation (643) 643
rosuvastatin calcium (640) 640
prevention (629) 629
peripheral vascular disease (623) 623
analysis (622) 622
hypercholesterolemia (619) 619
therapy (593) 593
drug therapy, combination (586) 586
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (580) 580
double-blind method (579) 579
statin (578) 578
time factors (562) 562
medicine, general & internal (561) 561
prospective studies (538) 538
drug therapy (537) 537
cardiovascular (534) 534
disease (530) 530
pyrroles - adverse effects (528) 528
care and treatment (527) 527
heptanoic acids - adverse effects (527) 527
simvastatin - therapeutic use (524) 524
cardiovascular disease (518) 518
cholesterol - blood (504) 504
anticholesteremic agents - administration & dosage (485) 485
mice (482) 482
research (482) 482
expression (476) 476
coronary-heart-disease (475) 475
c-reactive protein (469) 469
abridged index medicus (449) 449
lipids - blood (446) 446
anticholesteremic agents - pharmacology (428) 428
cardiovascular diseases (420) 420
statin therapy (416) 416
mortality (413) 413
oxidative stress (411) 411
cardiovascular agents (408) 408
triglycerides - blood (406) 406
cardiovascular-disease (402) 402
follow-up studies (398) 398
efficacy (389) 389
aged, 80 and over (386) 386
low density lipoproteins (377) 377
coronary heart disease (372) 372
fluorobenzenes - therapeutic use (371) 371
cholesterol, hdl - blood (366) 366
hypertension (365) 365
safety (362) 362
sulfonamides - therapeutic use (361) 361
biomarkers - blood (358) 358
cardiology (358) 358
pyrimidines - therapeutic use (355) 355
hyperlipidemias - drug therapy (354) 354
myocardial-infarction (353) 353
diabetes (345) 345
cardiovascular diseases - prevention & control (342) 342
medicine & public health (335) 335
coa reductase inhibitors (328) 328
disease models, animal (327) 327
drug interactions (327) 327
medicine, research & experimental (327) 327
biochemistry & molecular biology (325) 325
health aspects (315) 315
hypercholesterolemia - blood (314) 314
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7049) 7049
Chinese (97) 97
German (77) 77
Russian (69) 69
Spanish (47) 47
French (42) 42
Japanese (36) 36
Portuguese (22) 22
Polish (12) 12
Hungarian (11) 11
Italian (10) 10
Korean (8) 8
Turkish (7) 7
Ukrainian (6) 6
Swedish (5) 5
Czech (4) 4
Dutch (4) 4
Norwegian (4) 4
Danish (3) 3
Croatian (2) 2
Lithuanian (2) 2
Belarusian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
American Journal of Cardiology, The, ISSN 0002-9149, 2017, Volume 119, Issue 10, pp. 1584 - 1589
Abstract Coronary artery (CAC) and abdominal aortic calcium (AAC) on multi-detector computed tomography (MDCT... 
Cardiovascular | MORTALITY | CARDIAC & CARDIOVASCULAR SYSTEMS | METAANALYSIS | PREDICTOR | EVENTS | DEPOSITS | SCORES | VASCULAR CALCIFICATION | ATHEROSCLEROSIS | MELLITUS | DIABETES TRIAL VADT | Coronary Vessels - diagnostic imaging | Predictive Value of Tests | Follow-Up Studies | Calcium - metabolism | Humans | Middle Aged | Male | Aortic Diseases - metabolism | Coronary Vessels - metabolism | Incidence | Vascular Calcification - metabolism | Aorta, Abdominal - diagnostic imaging | Coronary Angiography - methods | Time Factors | Adult | Female | Retrospective Studies | Vascular Calcification - diagnosis | Aorta, Abdominal - metabolism | Multidetector Computed Tomography - methods | Aortic Diseases - diagnosis | Massachusetts - epidemiology | Disease Progression | Coronary Artery Disease - diagnosis | Coronary Artery Disease - complications | Aortic Diseases - complications | Coronary Artery Disease - epidemiology | Aortography | Development and progression | Cardiology | Risk factors | Atherosclerosis | Anticholesteremic agents | Smoking | Heart | Calcification (ectopic) | Ascorbic acid | C-reactive protein | Calcium | Body weight | Brain slice preparation | Lipids | Gender | Congestive heart failure | Body mass index | Computed tomography | Vitamin E | Aorta | Blood pressure | Children | Age | Hypertension | Creatinine | Medical imaging | Mortality | Health risks | Coronary artery | Thorax | Cigarette smoking | Cholesterol | Abdomen | Progeny | Algorithms | Body mass | Coronary vessels | Arteriosclerosis | Calcification | Atorvastatin | Skull | Diabetes | Health risk assessment | Cardiovascular diseases | Veins & arteries | Kidney transplantation | Coronary Artery Calcium | Cardiovascular Disease Risk Factors | Abdominal Aortic Calcium
Journal Article
PloS one, ISSN 1932-6203, 2014, Volume 9, Issue 2, p. e86317
.... The present study focuses on enhancing the therapeutic and anti cancer properties of atorvastatin calcium loaded BSA (ATV-BSA... 
APOPTOSIS | CELLS | DOCKING | MULTIDISCIPLINARY SCIENCES | CYTOTOXICITY | PROBE | BOVINE SERUM-ALBUMIN | DELIVERY | Hemolysis - drug effects | Pancreatic Neoplasms - metabolism | Pyrroles - pharmacokinetics | Reactive Oxygen Species - metabolism | Nanoparticles - chemistry | Heptanoic Acids - pharmacokinetics | Humans | Anticholesteremic Agents - chemistry | Spectroscopy, Fourier Transform Infrared | Anticholesteremic Agents - metabolism | Time Factors | Cattle | Adult | Serum Albumin, Bovine - chemistry | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Heptanoic Acids - pharmacology | Cell Survival - drug effects | Microscopy, Electron, Scanning | Pancreatic Neoplasms - pathology | Nanoparticles - ultrastructure | Spectrometry, Fluorescence | Antineoplastic Agents - chemistry | Atorvastatin Calcium | Microscopy, Confocal | Anticholesteremic Agents - pharmacokinetics | Pyrroles - pharmacology | Animals | Heptanoic Acids - chemistry | Cell Line, Tumor | Pyrroles - chemistry | Molecular Docking Simulation | Kinetics | Albumin | Chemotherapy | All terrain vehicles | Health aspects | Cancer | Biotechnology | Particle size | Calcium | Ethanol | Toxicity | Caveolin | Cytotoxicity | Cholesterol | Anticancer properties | Nanoparticles | Proteins | Studies | Endocytosis | Biomedical materials | Cell cycle | Process parameters | Atorvastatin | In vitro methods and tests | Nanotechnology
Journal Article
The American journal of clinical nutrition, ISSN 1938-3207, 2009, Volume 89, Issue 6, pp. 1799 - 1807
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 05/2018, Volume 71, Issue 21, pp. 2487 - 2488
... prediction) with statin therapy. High-sensitivity C-reactive protein (hsCRP), a marker of inflammation, and coronary artery calcium (CAC), a marker of coronary plaque... 
Calcification (ectopic) | C-reactive protein | Calcium | Coronary artery | Patients | Proteins | Studies | Hypotheses | Arteriosclerosis | Coronary vessels | Biomarkers | Atorvastatin | Statins
Journal Article
PloS one, ISSN 1932-6203, 04/2015, Volume 10, Issue 4, p. e0122577
.... It has been demonstrated that PDGF-BB is a critical mediator of VSMCs phenotypic switch. Atorvastatin calcium, a selective inhibitor of 3-hydroxy-3-methyl-glutaryl l coenzyme A (HMG-CoA... 
MAMMALIAN TARGET | VASCULAR INJURY | MIGRATION | INDUCED PROLIFERATION | MULTIDISCIPLINARY SCIENCES | IN-VIVO | ATHEROSCLEROSIS | SMOOTH-MUSCLE-CELLS | GROWTH-FACTOR | DIFFERENTIATION | EXPRESSION | Male | Dose-Response Relationship, Drug | Time Factors | Actin Cytoskeleton - drug effects | DNA - biosynthesis | Myocytes, Smooth Muscle - drug effects | Proto-Oncogene Proteins c-akt - metabolism | Proto-Oncogene Proteins c-sis - pharmacology | Myocytes, Smooth Muscle - metabolism | Actin Cytoskeleton - metabolism | Cells, Cultured | Becaplermin | Atorvastatin - pharmacology | Down-Regulation - drug effects | Muscle, Smooth, Vascular - cytology | Rats, Sprague-Dawley | Blotting, Western | Cell Shape - drug effects | DNA - genetics | Cell Movement - drug effects | Microscopy, Confocal | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Signal Transduction - drug effects | Cytoskeleton - metabolism | Cell Proliferation - drug effects | Cytoskeleton - drug effects | Enzymes | Cellular signal transduction | Platelet-derived growth factor | Muscle proteins | Antilipemic agents | Phosphorylation | Calcium | Secretion | Muscles | Phenotypic plasticity | Smooth muscle | AKT protein | Activation | Muscle contraction | Platelet-derived growth factor BB | Proteins | Signal transduction | Signaling | Calponin | Vascular diseases | Actin | Modulation | Atorvastatin | Cytoskeleton | Coenzyme A | Inhibition | Reductase | Transduction
Journal Article
Journal Article
Advanced pharmaceutical bulletin, ISSN 2251-7308, 2019, Volume 9, Issue 4, pp. 559 - 570
Journal Article
International journal of nanomedicine, ISSN 1178-2013, 2019, Volume 14, pp. 649 - 665
.... The hypolipidemic agent atorvastatin calcium (Ato) alleviates atherosclerosis by reducing plasma lipid and inflammatory factors... 
Atorvastatin calcium | Targeted codelivery | Antiatherosclerosis | Curcumin | Combined therapy | combined therapy | targeted codelivery | DRUG-DELIVERY | MACROPHAGES | MONOCYTE CHEMOATTRACTANT PROTEIN-1 | NANOSCIENCE & NANOTECHNOLOGY | PROLIFERATION | NANOPARTICLES | INFLAMMATORY MECHANISMS | E-SELECTIN | DEFICIENT | PHARMACOLOGY & PHARMACY | SIRNA | antiatherosclerosis | MODULATION | atorvastatin calcium | curcumin | Inflammation - pathology | Apolipoproteins E - deficiency | Curcumin - chemistry | Humans | Apolipoproteins E - metabolism | Inflammation - blood | Inflammation - drug therapy | Lipids - blood | Chemokine CCL2 - metabolism | Cell Death - drug effects | Interleukin-6 - metabolism | Cell Survival - drug effects | Atherosclerosis - pathology | Atherosclerosis - drug therapy | Curcumin - therapeutic use | Endothelial Cells - metabolism | Atorvastatin - therapeutic use | E-Selectin - metabolism | Atorvastatin - pharmacology | Static Electricity | Mice, Knockout | Atherosclerosis - blood | Drug Synergism | Particle Size | Intercellular Adhesion Molecule-1 - metabolism | Animals | Ligands | Endothelial Cells - pathology | Liposomes - ultrastructure | Endothelial Cells - drug effects | Drugs | Cytokines | Peptides | Cardiovascular disease | Lipids | Smooth muscle | Inflammation | Bioavailability | Gene expression | Cell adhesion & migration | Endothelium | Nanoparticles | Proteins | Hospitals | Polyethylene glycol | Atherosclerosis | Statins | Cancer
Journal Article
Journal of controlled release, ISSN 0168-3659, 05/2017, Volume 254, pp. 10 - 22
Atorvastatin calcium (ATV), a cholesterol-lowering agent, suffers from poor systemic availability (14... 
Atorvastatin calcium | Transdermal delivery | Oxidative stress | Nanotransfersomes | Hyperlipidemia | Liver toxicity | LASER-SCANNING MICROSCOPY | DRUG-DELIVERY | ULTRADEFORMABLE LIPOSOMES | DEPENDENT PATHWAYS | CARRIERS | CHEMISTRY, MULTIDISCIPLINARY | EDGE ACTIVATORS | NITRIC-OXIDE | PHARMACOLOGY & PHARMACY | SKIN | IN-VIVO EVALUATION | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Lecithins - metabolism | Polysorbates - chemistry | Rats, Wistar | Atorvastatin Calcium - administration & dosage | Biological Availability | Male | Polyethylene Glycols - chemistry | Administration, Cutaneous | Hydroxymethylglutaryl-CoA Reductase Inhibitors - chemistry | Nanocapsules - chemistry | Cholesterol - chemistry | Atorvastatin Calcium - toxicity | Lecithins - chemistry | Liver - drug effects | Esters - chemistry | Glycerol - analogs & derivatives | Glycerol - chemistry | Polyethylene Glycols - metabolism | Transdermal Patch | Glycerides - chemistry | Fatty Acids - chemistry | Hydroxymethylglutaryl-CoA Reductase Inhibitors - toxicity | Hyperlipidemias - drug therapy | Atorvastatin Calcium - chemistry | Skin Absorption | Permeability | Chemistry, Pharmaceutical | Particle Size | Animals | Poloxamer | Drug Liberation | Hyperlipidemias - chemically induced | Drug Delivery Systems - methods | Esters | Polyethylene glycol | Fatty acids | Liver | Transdermal medication | Membrane lipids | Enzymes | Low density lipoproteins
Journal Article